

Why Choose? DARPin Miniproteins as Isotope-Agnostic Vector for Targeted Alpha Therapies

Molecular Partners AG (SIX, NASDAQ: MOLN) is a clinical-stage biotech company developing targeted alpha radiotherapeutics leveraging its Radio-DARPin as isotope-agnostic vector amenable to a broad range of cancer targets and indications.

Breakthrough Radio-DARPin Therapy MP0712 for SCLC Patients

MP0712 is a Radio-DARPin therapeutic binding Delta-Like Ligand 3 (DLL3)—a tumor target highly expressed in most small cell lung cancers (SCLC) and other neuroendocrine carcinomas (NECs) but largely absent from healthy tissues. Paired with ^{212}Pb , a potent therapeutic isotope, MP0712 is designed to concentrate cell-killing radiation in DLL3-positive tumor lesions with exquisite precision.

Promising First-in-Patient Imaging Data

At the 8th Theranostics World Congress (January 2026, Cape Town), the team led by Prof. Mike Sathegke of the University of Pretoria and Steve Biko Academic Hospital presented compassionate-use imaging and dosimetry data from five patients who received ^{203}Pb -labeled MP0712 at the Nuclear Medicine Research Infrastructure (NuMerI) in South Africa. The images showed robust, specific tumor uptake with minimal uptake in healthy organs—mirroring MP0712's favorable biodistribution observed preclinically.

Patients spanned multiple DLL3-expressing malignancies including SCLC and other NECs suggest broad cross-tumor utility of MP0712. Dosimetry analyses suggest that delivery of effective doses to tumors while keeping normal-tissue exposure within safe limits is feasible, increasing confidence in the ongoing Phase 1 study and supporting MP0712's clinical development.

U.S. Phase 1/2a Trial—Recruiting Patients


Molecular Partners has fast-tracked MP0712 into a multi-center U.S. Phase 1/2a trial (NCT07278479, opened late 2025) for patients with advanced SCLC and other DLL3-expressing NECs. Primary objectives of the Phase 1 dose-escalation are to assess safety and determine the recommended Phase 2 dose of therapeutic ^{212}Pb -MP0712. A pre-treatment imaging step using MP0712 labeled with ^{203}Pb —a diagnostic match of ^{212}Pb —is included for biodistribution and dosimetry assessment prior to therapeutic dosing. The Phase 2a expansion will evaluate MP0712's anti-tumor efficacy.

Initial clinical data are anticipated later in 2026, potentially including safety findings as well as early signs of anti-tumor activity.


Isotope Interchangeability: A DARPin Advantage

At the 3rd Global Radiopharmaceuticals Development Summit (March 2026, Shanghai), Dr. Daniel Steiner, SVP

Radio-DARPin for Next-Gen Targeted Alpha Therapy



SPECT/CT Imaging with ^{203}Pb -MP0712 in a Patient with Metastatic Small Cell Lung Cancer



of Targeted Radio Therapeutics at Molecular Partners, presented preclinical data showing Radio-DARPin maintain similar biodistribution when swapped between isotopes. In murine models, two candidates achieved equivalent tumor uptake and clearance whether labeled with ^{177}Lu or ^{203}Pb —demonstrating that DARPin-driven biological targeting dominates distribution regardless of isotope and chelator choice.

This supports a powerful theranostic strategy: ^{203}Pb imaging accurately predicts therapeutic ^{212}Pb distribution, while ^{177}Lu models ^{225}Ac behavior. The ability to interchange alpha isotopes—particularly ^{212}Pb and ^{225}Ac —is a key competitive advantage of Radio-DARPin, enabling isotope-agnostic evaluation of candidates and

Continued on page 9. See *DARPin Isotope-Agnostic Vector*.

selection of the most suitable therapeutic isotope as late as with initial clinical data, without having to restart the entire development process.

Molecular Partners designs its Radio-DARPin candidates matching disease and target biology with vector and isotope properties to address unmet medical needs. DARPins (Designed Ankyrin Repeat Proteins) are a novel class of protein drugs which have been clinically-validated across several therapeutic areas and developed through to the registrational stage.

Full Value Chain Partnerships – Securing Isotope Supply & Capabilities

Orano Med (Lead-212): The strategic partnership began in 2024 and expanded early 2025 to encompass up to ten ²¹²Pb-based radiotherapeutic candidates, leveraging Orano Med's proprietary ²¹²Pb supply and targeted alpha therapy expertise and capabilities. In return, Molecular Partners' Radio-DARPin platform provides Orano Med an advanced targeting vector, creating a synergistic pipeline. MP0712, co-developed by both companies, progressed from concept to first-in-human trials within roughly one year.

Eckert & Ziegler (Actinium-225 & Lutetium-177): Announced in February 2026, this agreement enables development and manufacturing of Radio-DARPins incorporating ²²⁵Ac as therapeutic payload and ¹⁷⁷Lu as

imaging surrogate. This future-proofs the supply chain: while MP0712 currently focuses on ²¹²Pb, having ²²⁵Ac production in place enables exploring longer-lived alpha therapy as candidates advance. Eckert & Ziegler's ¹⁷⁷Lu provision—a workhorse isotope already used in FDA-approved therapies—also enables complementary diagnostic protocols.


These partnerships, together with the Company's Scientific Advisory Board chaired by nuclear medicine leader Prof. Ken Herrmann, strengthen the capabilities and infrastructure needed to deliver MP0712 globally and to build a multi-target pipeline in which each Radio-DARPin is armed with the optimal isotope.

Outlook: At this year's SNMMI conference the Company is presenting the design of the ongoing MP0712 Phase 1/2a study (poster #261055).

As the nuclear medicine community convenes

at SNMMI 2026, MP0712 exemplifies the convergence of molecular targeting with therapeutic isotopes—offering precision alpha therapy to tumors previously out of reach, and highlights how Molecular Partners' Radio-DARPin technology is rapidly translating into first-in-human clinical results.

US Phase 1/2a study
of MP0712 in SCLC
and other DLL3+ NECs



Make sense of complex radiation safety requirements

Launching or expanding radiopharmaceutical therapy requires more than equipment — it requires diligent regulatory compliance. Our new white paper gives your team clear, expert-driven guidance on licensing, facility design, radiation safety training and patient management.



Download the white paper now, and take the next step toward advancing your radiopharmaceutical therapy program